M Ventures

Altoida AG, founded in 2016 and based in Lucerne, Switzerland, specializes in developing a healthcare platform and application aimed at Alzheimer’s patients. The company's flagship product, the Altoida iPad-based application, is the first validated solution on the market designed to predict the risk of Alzheimer’s Disease before symptoms appear, functioning as a computational biomarker. The application employs the Neuro Motor Index (NMI), which measures subtle micro-errors and micro-movements during everyday tasks, allowing for early detection of cognitive decline up to six years prior to the onset of typical neurodegenerative symptoms. The NMI test is intended for use by healthcare professionals as an adjunctive tool and is not a stand-alone diagnostic method. Altoida's medical device is classified as an FDA Class II medical device and CE marked as Class I, enabling early screening for Mild Cognitive Impairment (MCI) and monitoring cognitive function. After a brief testing period, healthcare providers receive real-time access to comprehensive patient reports via a secure, HIPAA-compliant web dashboard, making cognitive health assessments more affordable and accessible.

AELER Technologies SA manufactures Internet of things (IoT) based smart containers for supply chain operations. The company offers AELER C-cube, a smart container, which provides insulation, encapsulation, sensors, and weight optimization features. It also develops a cloud based platform, AELER, which automates information flows, supports decision-making, and predicts analysis. It serves logistics and supply chain markets. The company was founded in 2016 and is headquartered in Lausanne, Switzerland.

iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.

SynSense is a leading-edge neuromorphic computing company. It provides dedicated mixed-signal/fully digital neuromorphic processors which overcome the limitations of legacy von Neumann computers to provide an unprecedented combination of ultra-low power consumption and low-latency performance. SynSense is founded in March 2017 based on advances in neuromorphic computing hardware developed at the Institute of Neuroinformatics of the University of Zurich and ETH Zurich. aiCTX is developing “full-stack” custom neuromorphic processors for a variety of artificial-intelligence (AI) edge-computing applications that require ultra-low-power and ultra-low-latency features, including autonomous robots, always-on co-processors for mobile and embedded devices, wearable health-care systems, security, IoT applications, and computing at the network edge.

FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company specializes in developing first-in-class therapeutic compounds for cancer treatment by targeting key molecular mechanisms related to DNA replication stress. This innovative approach aims to create targeted anticancer drugs that address critical aspects of cancer biology. As a privately-held entity, FoRx Therapeutics is committed to advancing its research and development efforts in the oncology space.

iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.

Altoida AG, founded in 2016 and based in Lucerne, Switzerland, specializes in developing a healthcare platform and application aimed at Alzheimer’s patients. The company's flagship product, the Altoida iPad-based application, is the first validated solution on the market designed to predict the risk of Alzheimer’s Disease before symptoms appear, functioning as a computational biomarker. The application employs the Neuro Motor Index (NMI), which measures subtle micro-errors and micro-movements during everyday tasks, allowing for early detection of cognitive decline up to six years prior to the onset of typical neurodegenerative symptoms. The NMI test is intended for use by healthcare professionals as an adjunctive tool and is not a stand-alone diagnostic method. Altoida's medical device is classified as an FDA Class II medical device and CE marked as Class I, enabling early screening for Mild Cognitive Impairment (MCI) and monitoring cognitive function. After a brief testing period, healthcare providers receive real-time access to comprehensive patient reports via a secure, HIPAA-compliant web dashboard, making cognitive health assessments more affordable and accessible.

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.

Inthera Bioscience AG is a private biopharmaceutical company based in Switzerland, established in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera employs a proprietary technology platform to create inhibitors of intracellular protein-protein interactions, which are designed to block aberrant cell signaling associated with cancer. By focusing on rationally designed oral agents, Inthera aims to enhance treatment outcomes for patients with solid tumors. The company is headquartered in Schlieren, Switzerland, and is committed to advancing innovative therapeutic solutions in oncology.

iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.

Inthera Bioscience AG is a private biopharmaceutical company based in Switzerland, established in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera employs a proprietary technology platform to create inhibitors of intracellular protein-protein interactions, which are designed to block aberrant cell signaling associated with cancer. By focusing on rationally designed oral agents, Inthera aims to enhance treatment outcomes for patients with solid tumors. The company is headquartered in Schlieren, Switzerland, and is committed to advancing innovative therapeutic solutions in oncology.

Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, focused on developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012, ObsEva aims to address significant medical needs in this area, particularly through its lead product, Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist intended to treat pain associated with endometriosis and heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. The company is also advancing OBE022, a selective oral prostaglandin F2α receptor antagonist for treating preterm labor in women between 24 to 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist designed to improve clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The founding team comprises experienced professionals in reproductive medicine and biopharmaceuticals, bringing a wealth of expertise to the company's mission.

Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012. It specializes in the discovery and development of therapeutics for neurodegenerative disorders, particularly focusing on conditions with significant unmet medical needs, such as progressive supranuclear palsy, orphan tauopathies, Alzheimer's disease, and Parkinson's disease. Asceneuron aims to address the challenges posed by tauopathies, which are currently untreatable and characterized by the accumulation of tau protein deposits in the brain, leading to severe neurodegeneration. The company seeks to develop small molecule drugs that can provide effective treatment options, as existing therapies for Alzheimer's disease and related conditions offer limited benefits. With an increasing aging population, the burden of neurodegenerative diseases is expected to grow, highlighting the urgent demand for innovative and better-tolerated therapeutic solutions. Asceneuron operates as a subsidiary of Merck KGaA, reinforcing its commitment to advancing treatments in this critical area of healthcare.

Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease.

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.